Modulation of growth factors by growth hormone in children with chronic renal failure

David R. Powell, Frances Liu, Bonita K. Baker, Raymond L. Hintz, Phillip Lee, Susan K. Durham, Eileen D. Brewer, James W. Frane, Sandra L. Watkins, Ronald J. Hogg

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Anthropometric measurements and circulating growth factors were studied serially in 44 prepubertal children with growth failure and chronic renal failure (GFR = 10 to 40 ml/min/1.73 m2) who were randomized to receive either recombinant human growth hormone (rhGH; N = 30) or no treatment (N = 14). RhGH was given as Nutropin, 0.05 mg/kg/day, and the studies were carried out at baseline and after 3 and 12 months. At baseline, serum insulin-like growth factor binding protein (IGFBP)-1 and -2 levels were, while IGFBP-3 levels were not, higher than those of children with normal renal function. In addition, height SDS at baseline correlated inversely with serum IGFBP-2 levels (r = -0.461, P = 0.0016), but did not correlate significantly with any other factor. After 12 months of study, the 30 children receiving rhGH showed: (i) greater increase in height (9.1 ± 2.8 vs. 5.5 ± 1.9 cm, P < 0.0001); (ii) increases in serum levels of IGF-I, IGF-II, free IGF-I, IGFBP-3 and acid labile subunit (ALS); (iii) a greater decrease in serum IGFBP-1 levels; and (iv) no significant difference in serum IGFBP-2 levels, when compared to the 14 control patients. The change in height SDS after 12 months of rhGH (+ 0.8) in the 30 treated children correlated significantly and positively with serum ALS, IGFBP-3, total IGF, IGF-I, IGF-II and free IGF-I levels measured during treatment. These observations suggest that, in children with growth failure associated with chronic renal failure: (i) IGFBP-2, and not IGFBP-3, is likely to be a growth inhibitor; (ii) rhGH stimulates catch-up growth in part by increasing serum levels of IGF peptides; and (iii) linear growth is influenced by the balance between growth stimulating IGFs and growth inhibitory IGFBPs.

Original languageEnglish (US)
Pages (from-to)1970-1979
Number of pages10
JournalKidney International
Volume51
Issue number6
StatePublished - 1997
Externally publishedYes

Fingerprint

Growth Hormone
Chronic Kidney Failure
Intercellular Signaling Peptides and Proteins
Insulin-Like Growth Factor Binding Protein 2
Insulin-Like Growth Factor Binding Protein 3
Insulin-Like Growth Factor I
Serum
Growth
Insulin-Like Growth Factor Binding Protein 1
Insulin-Like Growth Factor II
Human Growth Hormone
Insulin-Like Growth Factor Binding Proteins
Growth Inhibitors
Kidney
Peptides
Acids
Therapeutics

ASJC Scopus subject areas

  • Nephrology

Cite this

Powell, D. R., Liu, F., Baker, B. K., Hintz, R. L., Lee, P., Durham, S. K., ... Hogg, R. J. (1997). Modulation of growth factors by growth hormone in children with chronic renal failure. Kidney International, 51(6), 1970-1979.

Modulation of growth factors by growth hormone in children with chronic renal failure. / Powell, David R.; Liu, Frances; Baker, Bonita K.; Hintz, Raymond L.; Lee, Phillip; Durham, Susan K.; Brewer, Eileen D.; Frane, James W.; Watkins, Sandra L.; Hogg, Ronald J.

In: Kidney International, Vol. 51, No. 6, 1997, p. 1970-1979.

Research output: Contribution to journalArticle

Powell, DR, Liu, F, Baker, BK, Hintz, RL, Lee, P, Durham, SK, Brewer, ED, Frane, JW, Watkins, SL & Hogg, RJ 1997, 'Modulation of growth factors by growth hormone in children with chronic renal failure', Kidney International, vol. 51, no. 6, pp. 1970-1979.
Powell DR, Liu F, Baker BK, Hintz RL, Lee P, Durham SK et al. Modulation of growth factors by growth hormone in children with chronic renal failure. Kidney International. 1997;51(6):1970-1979.
Powell, David R. ; Liu, Frances ; Baker, Bonita K. ; Hintz, Raymond L. ; Lee, Phillip ; Durham, Susan K. ; Brewer, Eileen D. ; Frane, James W. ; Watkins, Sandra L. ; Hogg, Ronald J. / Modulation of growth factors by growth hormone in children with chronic renal failure. In: Kidney International. 1997 ; Vol. 51, No. 6. pp. 1970-1979.
@article{61b772a0bc54493cb8e9f8a411138cc5,
title = "Modulation of growth factors by growth hormone in children with chronic renal failure",
abstract = "Anthropometric measurements and circulating growth factors were studied serially in 44 prepubertal children with growth failure and chronic renal failure (GFR = 10 to 40 ml/min/1.73 m2) who were randomized to receive either recombinant human growth hormone (rhGH; N = 30) or no treatment (N = 14). RhGH was given as Nutropin, 0.05 mg/kg/day, and the studies were carried out at baseline and after 3 and 12 months. At baseline, serum insulin-like growth factor binding protein (IGFBP)-1 and -2 levels were, while IGFBP-3 levels were not, higher than those of children with normal renal function. In addition, height SDS at baseline correlated inversely with serum IGFBP-2 levels (r = -0.461, P = 0.0016), but did not correlate significantly with any other factor. After 12 months of study, the 30 children receiving rhGH showed: (i) greater increase in height (9.1 ± 2.8 vs. 5.5 ± 1.9 cm, P < 0.0001); (ii) increases in serum levels of IGF-I, IGF-II, free IGF-I, IGFBP-3 and acid labile subunit (ALS); (iii) a greater decrease in serum IGFBP-1 levels; and (iv) no significant difference in serum IGFBP-2 levels, when compared to the 14 control patients. The change in height SDS after 12 months of rhGH (+ 0.8) in the 30 treated children correlated significantly and positively with serum ALS, IGFBP-3, total IGF, IGF-I, IGF-II and free IGF-I levels measured during treatment. These observations suggest that, in children with growth failure associated with chronic renal failure: (i) IGFBP-2, and not IGFBP-3, is likely to be a growth inhibitor; (ii) rhGH stimulates catch-up growth in part by increasing serum levels of IGF peptides; and (iii) linear growth is influenced by the balance between growth stimulating IGFs and growth inhibitory IGFBPs.",
author = "Powell, {David R.} and Frances Liu and Baker, {Bonita K.} and Hintz, {Raymond L.} and Phillip Lee and Durham, {Susan K.} and Brewer, {Eileen D.} and Frane, {James W.} and Watkins, {Sandra L.} and Hogg, {Ronald J.}",
year = "1997",
language = "English (US)",
volume = "51",
pages = "1970--1979",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Modulation of growth factors by growth hormone in children with chronic renal failure

AU - Powell, David R.

AU - Liu, Frances

AU - Baker, Bonita K.

AU - Hintz, Raymond L.

AU - Lee, Phillip

AU - Durham, Susan K.

AU - Brewer, Eileen D.

AU - Frane, James W.

AU - Watkins, Sandra L.

AU - Hogg, Ronald J.

PY - 1997

Y1 - 1997

N2 - Anthropometric measurements and circulating growth factors were studied serially in 44 prepubertal children with growth failure and chronic renal failure (GFR = 10 to 40 ml/min/1.73 m2) who were randomized to receive either recombinant human growth hormone (rhGH; N = 30) or no treatment (N = 14). RhGH was given as Nutropin, 0.05 mg/kg/day, and the studies were carried out at baseline and after 3 and 12 months. At baseline, serum insulin-like growth factor binding protein (IGFBP)-1 and -2 levels were, while IGFBP-3 levels were not, higher than those of children with normal renal function. In addition, height SDS at baseline correlated inversely with serum IGFBP-2 levels (r = -0.461, P = 0.0016), but did not correlate significantly with any other factor. After 12 months of study, the 30 children receiving rhGH showed: (i) greater increase in height (9.1 ± 2.8 vs. 5.5 ± 1.9 cm, P < 0.0001); (ii) increases in serum levels of IGF-I, IGF-II, free IGF-I, IGFBP-3 and acid labile subunit (ALS); (iii) a greater decrease in serum IGFBP-1 levels; and (iv) no significant difference in serum IGFBP-2 levels, when compared to the 14 control patients. The change in height SDS after 12 months of rhGH (+ 0.8) in the 30 treated children correlated significantly and positively with serum ALS, IGFBP-3, total IGF, IGF-I, IGF-II and free IGF-I levels measured during treatment. These observations suggest that, in children with growth failure associated with chronic renal failure: (i) IGFBP-2, and not IGFBP-3, is likely to be a growth inhibitor; (ii) rhGH stimulates catch-up growth in part by increasing serum levels of IGF peptides; and (iii) linear growth is influenced by the balance between growth stimulating IGFs and growth inhibitory IGFBPs.

AB - Anthropometric measurements and circulating growth factors were studied serially in 44 prepubertal children with growth failure and chronic renal failure (GFR = 10 to 40 ml/min/1.73 m2) who were randomized to receive either recombinant human growth hormone (rhGH; N = 30) or no treatment (N = 14). RhGH was given as Nutropin, 0.05 mg/kg/day, and the studies were carried out at baseline and after 3 and 12 months. At baseline, serum insulin-like growth factor binding protein (IGFBP)-1 and -2 levels were, while IGFBP-3 levels were not, higher than those of children with normal renal function. In addition, height SDS at baseline correlated inversely with serum IGFBP-2 levels (r = -0.461, P = 0.0016), but did not correlate significantly with any other factor. After 12 months of study, the 30 children receiving rhGH showed: (i) greater increase in height (9.1 ± 2.8 vs. 5.5 ± 1.9 cm, P < 0.0001); (ii) increases in serum levels of IGF-I, IGF-II, free IGF-I, IGFBP-3 and acid labile subunit (ALS); (iii) a greater decrease in serum IGFBP-1 levels; and (iv) no significant difference in serum IGFBP-2 levels, when compared to the 14 control patients. The change in height SDS after 12 months of rhGH (+ 0.8) in the 30 treated children correlated significantly and positively with serum ALS, IGFBP-3, total IGF, IGF-I, IGF-II and free IGF-I levels measured during treatment. These observations suggest that, in children with growth failure associated with chronic renal failure: (i) IGFBP-2, and not IGFBP-3, is likely to be a growth inhibitor; (ii) rhGH stimulates catch-up growth in part by increasing serum levels of IGF peptides; and (iii) linear growth is influenced by the balance between growth stimulating IGFs and growth inhibitory IGFBPs.

UR - http://www.scopus.com/inward/record.url?scp=8244233166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8244233166&partnerID=8YFLogxK

M3 - Article

VL - 51

SP - 1970

EP - 1979

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 6

ER -